Passive immunotherapy for measles infection - measles (MEV) causes disease worldwide despite efforts towards eradication by vaccine, primarily because IT is readily spread between people
Active Grant Awarded
- Award ID
- R01AI195589
- Recipient
-
The Trustees Of Columbia University In The City Of New York UEI QHF5ZZ114M72
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $855,113
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 13% complete
- Place of performance
- New York, NY 10032, USA
Award details come from USAspending.gov.
About this award
The National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services' National Institutes of Health, awarded The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, $855,113 on March 27, 2026, under Allergy and Infectious Diseases Research (CFDA 93.855) for Grant R01AI195589. The grant funds identification and production of anti-F neutralizing monoclonal antibodies against the measles virus fusion protein, building a defined cocktail of long-lasting antibodies for future clinical use, and evaluates the protection that anti-F passive immunotherapy provides. Work is aimed at people with impaired cellular immunity who cannot be vaccinated with the live measles vaccine. Aim 1 covers antibody production, selection, and epitope characterization, including a study of viral escape mutants. Aim 2 covers pre-exposure and post-exposure efficacy testing. Work is performed in New York, New York 10032, with a period of performance through March 31, 2031. La Jolla Institute for Immunology, doing business as La Jolla Institute For Allergy & Immunology, is the sub-recipient under sub-award R01AI195589-GG021456-01, dated August 31, 2026. It delivers the protein expression and purification, mouse-derived antibody humanization, epitope mapping and cryo-electron microscopy structural studies, escape-mutant characterization, and purified antibodies for in vivo protection studies.
Description
Acute MEV infection causes immune amnesia, increasing susceptibility to other infectious diseases. In addition, rare but severe neurological complications can develop several years after measles due to persistent MEV infection of the central nervous system (CNS). People with impaired cellular immunity are at increased risk of developing severe measles but often cannot be vaccinated since the vaccine virus itself can lead to fatal illness in this population. There is no specific therapy for acute or persistent MEV manifestations. The only available intervention beside vaccination is hyperimmune sera from vaccinated individuals. The current vaccine elicits antibodies directed against the two envelope glycoproteins, the receptor-binding hemagglutinin and the fusion(F) protein. The antibodies against the hemagglutinin are neutralizing, while current-vaccine-elicited antibodies against the fusion protein are not. This contrasts with wild type induced immunity that elicits effective anti-F neutralizing antibodies. This indicates a clear shortcoming of the current vaccine (i.e., inability to elicit anti-F neutralizing antibodies) that affects the potency of hyperimmune sera obtained from vaccinated people. We have recently identified several anti-F neutralizing antibodies, and we propose to identify several others to build a defined cocktail of long-lasting monoclonal antibodies for future clinical application. The proposed work will address two specific aims: 1. Production and selection of anti-F neutralizing antibodies. 2. Evaluate the protection afforded by anti-F protein passive immunotherapy. Our application will significantly impact the growing number of severely immune- compromised individuals who cannot be vaccinated with the current live MEV vaccine and would benefit from a defined cocktail of neutralizing monoclonal antibodies.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| La Jolla Institute For Immunology | $274,500 |
Quick answers
Who received award R01AI195589?
R01AI195589 was awarded to The Trustees Of Columbia University In The City Of New York by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 27, 2026.
How much is award R01AI195589 worth?
$855,113 has been obligated on R01AI195589.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award